Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

IBOGAINE

NFPA

PRODUCT USE

In the treatment of heroin and other addictions. Early data suggests that for many
patients, a period of approximately two years of intermittent treatments may be required
to attain the goal of long term abstinence from narcotics and stimulants. The majority of
patients treated with Ibogaine remain free from chemical dependence for a period of three
to six months after a single dose. Ibogaine is not addictive. Ibogaine is an indole
alkaloid of the iboga group, isolated from the root (1.27%), rootbark (2- 6%), stems
(1.95%) and leaves (0.35%) of the shrub Tabernanthe iboga Baill, Apocynaceae, found in
Africa and other Apocynaceae. Interatomic distances are found to be similar to those of
serotonin. African natives purportedly self- administer iboga extracts, while stalking
game, thus remaining motionless for as long as 2- days whilst still retaining mental
alertness. Ibogaine is a psychoactive substance which, in preclinical studies, reduced the
tendency of addicts to administer both cocaine and morphine, as well as attenuating the
symptoms of morphine withdrawal. Ibogaine' s ability to treat nicotine dependence has been
observed in poly- drug dependent subjects treated primarily for opiate and/or cocaine use.
Ibogaine binds to NMDA receptor complexes and the kappa opiate receptor; in addition it
effects dopamine production (dopamine is a substance hypothesised to be responsible for
reinforcing the pleasurable effects of drugs of abuse) Ibogaine is a controlled substance
(hallucinogen) in the U.S. Code of Federal Regulations, Title 21 Part 1308 11 (1985)

SYNONYMS

C20-H26-N2-O, "ibogamine, 12-methoxy-", "ibogamine, 12-methoxy-", (-)-ibogaine, 12-
methoxyibogamine, 12-methoxyibogamine, Endabuse, Ibogain, "NIH 10567", "iboga alkaloid"

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

Harmful if swallowed.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.  Considered an unlikely route of entry in commercial/industrial environments.  

EYE

  Although the material is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn).  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Toxic effects may result from skin absorption.  

INHALED

  Inhalation may produce health damage*.  The material is not thought to produce respiratory irritation (as classified using animal models). Nevertheless inhalation of the material, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.  Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.  

CHRONIC HEALTH EFFECTS

  Principal routes of exposure are usually by skin contact/absorption and inhalation of generated dust.  Repeated use of psychotomimetic substances may produce flashback with hallucinations, distortion of the perception of time, space, and self-image. This may be spontaneous and occur many months after the last dose. Tolerance and psychological dependence may occur.